Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children

← catalyst calendar

NCT01604395 · readout in 2,326 d

Sponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.

Phase
Status
Recruiting
Study type
Observational
Enrollment
6,000estimated
Sites
1
Country
South Korea

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
StartJan 2012not statedWhen the study began enrolling
Primary completion2032-12-31estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2032-12-31estimatedThe whole study's end, after follow-up
First posted2012-05-23estimatedWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2021-02-21actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Growth Hormone Deficiency
  • Turner Syndrome
  • Chronic Renal Failure
  • Small for Gestational Age
  • Idiopathic Short Stature

Primary outcome

what the primary-completion date above is the date OF
Safety measure : adverse event
measured up to 2 years after epiphyseal closure

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed